Relay Therapeutics (RLAY) Operating Leases (2020 - 2025)
Historic Operating Leases for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $29.7 million.
- Relay Therapeutics' Operating Leases fell 3296.75% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year decrease of 3296.75%. This contributed to the annual value of $42.8 million for FY2024, which is 1180.78% down from last year.
- According to the latest figures from Q3 2025, Relay Therapeutics' Operating Leases is $29.7 million, which was down 3296.75% from $30.7 million recorded in Q2 2025.
- In the past 5 years, Relay Therapeutics' Operating Leases registered a high of $54.6 million during Q3 2022, and its lowest value of $20.0 million during Q2 2022.
- For the 5-year period, Relay Therapeutics' Operating Leases averaged around $37.8 million, with its median value being $42.8 million (2024).
- Its Operating Leases has fluctuated over the past 5 years, first soared by 15524.75% in 2023, then tumbled by 3300.7% in 2025.
- Quarter analysis of 5 years shows Relay Therapeutics' Operating Leases stood at $21.1 million in 2021, then skyrocketed by 153.92% to $53.5 million in 2022, then decreased by 9.28% to $48.5 million in 2023, then fell by 11.81% to $42.8 million in 2024, then plummeted by 30.6% to $29.7 million in 2025.
- Its Operating Leases was $29.7 million in Q3 2025, compared to $30.7 million in Q2 2025 and $41.2 million in Q1 2025.